Skip to main content

Table 3 Evolution of the treatment response expressed by different standardised measures

From: Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration

F/U (months)

ACRpedi70 (%)

ACRpedi90 (%)

JADAS inactive (%)

JADAS low activity (%)

CID (%)

3

28.6

12.7

5.5

21.8

9.1

6

50.9

42.9

32.7

47.2

30.9

9

56.4

50.9

43.6

54.5

47.2

12

70.9

63.6

56.4

61.8

56.4

  1. F/U, Follow-up visit; CID, Clinically Inactive Disease [40]
  2. Results for 55 patients are shown. Patients who received biologics and/or who withdrew MTX were considered non-responders from the time point of starting the biologic or stopping MTX